• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report Product Image

Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report

  • ID: 344097
  • October 2010
  • Region: Global
  • 565 Pages
  • Global Industry Analysts, Inc

This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ million by the following Therapeutic Categories:

- Glaucoma
- Anti-allergy
- Anti-infective
- Dry Eye
- Anti-inflammation
- Back of Eye
- Others.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.

The report profiles 95 companies including many key and niche players such as Akorn, Inc., Alcon, Inc., Allergan, Inc., Alimera Sciences, Inc., Bausch & Lomb, Inc., Genvec, Inc., GlaxoSmithKline Plc, Inspire Pharmaceuticals, Inc., ISTA Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Ophthalmics, Opko Health, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., QLT, Inc., Santen Pharmaceutical Co., and Santen Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

OPHTHALMIC PHARMACEUTICAL DRUGS - A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 2
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3

2. INDUSTRY OVERVIEW 4
Present Scenario and Outlook 4
Current & Future Analysis 4
Patent Expiries to Check Market Growth 4
New Drugs to Sustain Growth 5
A Curtain Raiser 5
Drugs Developed in the Recent Past 5
What the Future Holds in Store? 6
Where Does the Opportunity Lie? 6
In the Shifting Demographics 6
Which Disease Segment Offers Abundant Opportunities for R&D
Initiatives 7
Leading Companies & Their Areas of Research Interest/Focus 8
Business Opportunities in Ophthalmology: A Fact Sheet 8
Impediments in Picking the Ripe & Low Hanging Opportunities 9
Low Patient Compliance 9
What's the Antidote to Low Patient Compliance? 9
Innovation in Ophthalmic Pharmaceuticals: How Does It Help
Patients? 10
An Unequivocal Discussion About Ocular Drug Design and Delivery 10
Why Understanding of the Metabolic Activity of the Eye is
Important? 10
Pitfalls of Traditional Ocular Treatment 11
Ophthalmic Drug Delivery: A Recapitulation of Facts 12
Antidotes to Low Delivery of Ocular Drugs & High Side Effects 13
Prodrug 13
Soft Drugs (SDs) 14
Soft Corticosteroids 14
Drug Penetration Enhancers 14
Chitosan Based Drugs & Drug Delivery Systems 15
How Chitosan is used to Improve Ocular Drug Retention On
the Eye's Surface? 15
The Future of Ophthalmic Drug Delivery 16
A Straight Talk About Ophthalmic Drug Delivery Technologies 16
High Flying Expectations of Blistering Pace of Drug
Development Grounded 16
First Generation Advancements Made in Ocular Drugs 17
Second Generation Advancements Made in Ocular Drugs 17
Limiting Factors 18

3. MARKET DYNAMICS 19
Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty 19
Ophthalmic Inserts Flaunt the Potential to Eclipse the
Popularity of Eye Drops 19
Rising Incidences of Glaucoma: A Business Case for Ophthalmic
Drugs 20
Lack of Awareness Creates Huge Burden 21
Financial Costs of Glaucoma Plague Developed and Developing
Countries 21
Aging Population & Environmental Factors Drive Growth 22
Increase in Healthcare Spending 22
Opportunities Abound in the Developing Countries 23
Innovative Products Lend Traction to Growth 23
Reimbursements: “Under the Umbrella” 23
Pricing Statistics On Select Ophthalmic Drugs in the US (
2006) - A Perspective Builder 24
Price Changes for Select Ophthalmic Drugs in the Year 2005 25

4. AN OVERVIEW OF OPHTHALMIC DRUGS 26
Anti Viral Drugs 26
Adenoviral Infections 26
Herpes Simplex Virus 26
Herpes Zoster (Varicella Zoster Disease) 26
Corticosteroids 27
Loteprednol 27
Prednisolone 27
Dexamethasone 28
Fluorometholones 28
Fluorometholone Alcohol 28
Fluorometholone Acetate 29
Rimexolone 29
Clinical Efficacy of Steroids 29
Topical Corticosteroid Drugs 30
Tapering of Steroid Intake 30
Non-Steroids Anti Inflammatory Drugs (NSAID) 31
Use of Topical NSAIDs 31
Topical & Systemic NSAIDs 31
Ketorolac: A Potent NSAID 32
Non-Steroidal Anti-Inflammatory Drugs 32
Antibiotics 32
Sodium Sulfacetamide 32
Sulfisoxazole 33
Bacitracin 33
Bacitracin and Polymyxin B: A Powerful Duo 34
Bacitracin, Polymyxin B and Neomycin: Three To Tango 34
Trimethoprim with Polymyxin B 34
Chloramphenicol 35
Erythromycin 35
Gentamicin and Tobramycin 35
Fluoroquinolones 36
Types of Fluoroquinolones 36
Ciprofloxacin 36
Gatifloxacin 36
Levofloxacin 36
Moxifloxacin 37
Ofloxacin 37
Topical Antibiotic Drugs 37
Ophthalmic Antihistamines 38
Azelastine 38
Emedastine 38
Epinastine 38
Ketotifen 38
Olopatadine 39
Ophthalmic Mast-Cell Stabilizers 39
Cromolyn 39
Nedocromil Sodium 39
Pemirolast 39
Drugs to Treat Glaucoma 40
Beta-Adrenergic Blockers or "Beta Blockers" 40
Timolol 40
Levobunolol 40
Carteolol 41
Metipranolol 41
Betaxolol 41
Alpha-Adrenergic Agonists 41
Carbonic Anhydrase Inhibitors 42
Acetazolamide 42
Dorzolamide 42
Acetazolamide & Dorzolamide: How Good Is the Combo? 43
Miotics 43
Prostaglandins 43
Mydriatics & Cycloplegics 43
Side Effects 44
Over-The-Counter (OTC) Ophthalmic Preparations 44
Artificial Tears 44
Lubricating Ointments 45
Mast Cell Stabilizers 45
Antihistamines 45
Phenylephrine 46
Naphazoline 46
Xylometazoline 46
Astringents 46
Over-The-Counter Ophthalmic Preparations 47
A Directory Listing of Major Ophthalmic Pharmaceutical Drugs 48
Formulary Anti- Glaucoma Drugs 48
Non-Formulary Anti- Glaucoma Drugs 49
Formulary Topical Anti-Glaucoma Drugs 49
Formulary Ophthalmic Antiinfective/Corticosteroids Drugs 50
Non-Formulary Ophthalmic Antiinfective/ Corticosteroids Drugs 50
Formulary Ophthalmic Corticosteroid Drugs 51
Non-Formulary Ophthalmic Corticosteroid Drugs 51
Formulary Ophthalmic Topical Antibacterial Drugs 52
Non-Formulary Ophthalmic Topical Antibacterial Drugs 53
Formulary Ophthalmic Topical Antiviral Drugs 53
Other Ophthalmic Formulary Drugs 53
Other Ophthalmic Non-Formulary Drugs 54
Pipeline Drugs 56

5. OPHTHALMIC DISORDERS: A FREEZE FRAME 57
The Human Eye: A Remarkable & Intriguing Organ of Sight 57
The Outer Layer 57
The Middle Layer 57
The Inner Layer 58
Common Ophthalmic Disorders: An Exposition 58
Cataract 58
Causes 58
Types of Cataract 59
Treatment Strategies 59
How Widespread is the Disease? 60
Glaucoma 60
Who's At Risk? 61
Types of Glaucoma 61
Primary Open Angle Glaucoma (POAG) 61
Acute Angle-Closure Glaucoma (AACG) 61
Congenital Glaucoma 62
Secondary Glaucoma 62
Treatment Strategies 62
Anti- Glaucoma Ophthalmic Drugs 63
Table 1: Global Market for Glaucoma Pharmaceuticals (2008):
Percentage Value Share Breakdown of Leading Players -
Pfizer, Inc., Allergan, Inc., Merck & Co., Alcon, Ista
Pharmaceuticals and Others (includes corresponding
Graph/Chart) 63

Table 2: Leading Glaucoma Pharmaceutical Products in the
Global Market (Excluding US) (2008, 2010 & 2012):
Percentage Breakdown of Value Sales for Xalatan/ Xalcom,
Cosopt/Trusopt, Travatan/ Extravan, Lumigan/Ganfort,
Alphagan/Combigan, Timoptic/ XE, Generic Timolol and Others
(includes corresponding Graph/Chart) 64
How Widespread is the Disease? 64
Table 3: Prevalence of Glaucoma in the World: Year 1999 and
2006 A Comparison (In 000 Individuals) (includes
corresponding Graph/Chart) 65
Is Marijuana A Potential Cure? 66
Age-Related Macular Degeneration (AMD) 66
Types of AMD 66
Dry AMD (Non-Neovascular) 66
Wet AMD (Neovascular) 67
Causes 67
Treatment Strategies 67
Nutrition & AMD 68
Diabetic Retinopathy 68
How Widespread is the Disease? 68
Table 4: Diabetic Retinopathy Patient Prevalence in the US
by Diabetes Type: 2006-2015 (In Thousand Patients)
(includes corresponding Graph/Chart) 69

Table 5: Diabetic Retinopathy Patient Prevalence in the US
by Age Group: 2006-2012 (includes corresponding
Graph/Chart) 69

Table 6: Diabetic Retinopathy Prevalence in Type-1 Diabetic
Patients in the US by Age Group: 2006-2012 (includes
corresponding Graph/Chart) 70
Treatment Strategies 70
Market Awaits First Approved Drug
Off-label Use Continues 71
Diabetic Retinopathy Drug Market to Post Dramatic Growth 71
Select Pipeline Drugs in Diabetic Retinopathy Market 72
Additional Trials Delay Arxxant's Launch 72
Lucentis Shows Promise in Diabetic Retinopathy Treatment 73
Pycnogenol Continues to Appeal to Researchers 74
Robo4 Protein - A Potential Therapeutic for Diabetic
Retinopathy 74
Bevacizumab Bodes Potential As An Adjunct to Surgery PDR
Treatment 75
Ocular Allergies 75
Treatment Strategies 76
Immunotherapy: A Popular Anti-Allergy Treatment Approach 76
Ocular Inflammation: A Symptom of Ocular Allergies 76
How Can Allergies Be Prevented? 77
Conjunctivitis (Pink Eye) 78
Types of Conjunctivitis 78
Pathogenesis 79
Treatment Strategies 79
Keratitis 80
Types of Keratitis 80
Treatment Strategies 80
Dry Eye 81
Why Are Tears So Crucial for Normal Eye Health? 81
What Causes Dry Eye? 82
Treatment Strategies 82
Refractive Errors 82
Causes for Refractive error 83
Treatment for Refractive Errors 83
Cost of Treatment 83
Factors contributing to the Difference in Surgery Costs 84

6. FDA APPROVALS AND PRODUCT LAUNCHES 85
Zymaxid Obtains US FDA Approval 85
Carco Introduces Azelastine Ophthalmic Solution, 0.05% 85
Fera Pharmaceuticals Launches Neptazane Tablets 85
Banyu Pharmaceutical Introduces Cosopt Combinational
Ophthalmic Solution 85
Bausch & Lomb Launches Soothe Xtra Hydration Eye Drops in the US 85
Akorn Secures FDA Clearance for Erythromycin Ophthalmic Ointment 86
Teva Launches New Dorzolamide Hydrochloride Ophthalmic Solution 86
Caraco Pharmaceutical Laboratories Introduces New Ophthalmic Drug 86
Auxano Diagnostics Introduces Novel Point-of-Care Indicator
System 86
Senju Pharmaceutical to Launch LUMIGAN® Ophthalmic Solution in
Japan 86
Sirion Receives FDA Approval for Zirgan 87
ISTA Pharmaceuticals Obtains FDA Approval for BepreveTM 87
Aton Pharma Reintroduces TIMOPTIC® in OCUDOSE® 87
Novagali Pharma Obtains FDA Clearance for Phase III Study for
Catioprost 88
Allergen Obtains FDA Approval for New Ophthalmic Product 88
Akorn Receives FDA Approval for Ciprofloxacin HCl Ophthalmic
Solution USP 88
Akorn Introduces Akten Gel 88
Sirion Launches Topical Ophthalmic Drug 88
FDC Obtains FDA Approval for Ciprofloxacin Ophthalmic Solution 89
Novagali Pharma to Introduce Cationorm® in France 89
Allergan Obtains FDA Clearance for Combigan 89

7. FDA APPROVALS AND PRODUCT APPROVALS LAUNCHES IN THE RECENT PAST -
A PERSPECTIVE BUILDER 90
Novagali Obtains FDA Approval of Nova22007 IND for Ph III Trial 90
Alimera Conducts Phase III Medidur Trial 90
ISTA Pharmaceuticals Files NDA for Xibrom™ QD 90
AzaSite Receives FDA Approval 90
Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections 91
Alimera Sciences Receives FDA Approval 91
Alcon Receives Approval for Vegamox™ Ophthalmic Solution in Japan 91
Alcon Receives Marketing Approval for Patanol® in Japan 91
Allergan Receives FDA Approval for Lumigan® 92
Allergan's Ganfort® Receives Pan European License 92
Pfizer Receives Approval from EC to Market Macugen® 92
Akorn Gets Nod for Conducting Clinical Trial of AK-1015 92
Genentech ‘s Lucentis Receives FDA Approval 92
MacuSight Receives FDA Approval for IND Application of Sirolimus 93
Sami Labs Receives Approval for Ocufors 93
Toyamo and Nidek Obtain Manufacturing Approval for Quinolone
Ophthalmic Solutions 93
Reckitt Benckiser Launches Two Eye Care Products 93
Alcon Launches DUOTRAV for Glaucoma Treatment 93
Macugen® Receives European Regulatory Approval 93
Rohto Pharmaceutical Launches Switch OTC Ophthalmic Drug 94
Indoco Remedies to Launch Ophthalmic Drugs in America 94
Alcons NEVANAC Receives FDA Approval 94
Fougera Obtains Approval for MetroGel® 94
Allergan's Alphagan P Receives FDA Approval 95
Santen Obtains Approval for Manufacturing and Marketing PAPILOCK 95
Akorn Launches Ophthalmic Drug Products 95
AlphaRx Formulates the Ophthalmic Product, Binoxan™ 95
Alimera Sciences Introduces Online Consumer Ordering Facility 95
Fougera Adds Two Novel Products to its Ophthalmic Product Line 95
Micro Vision Launches Anti-Glaucoma Drugs 96
Alcon Receives FDA Approval for Adding Susceptible Pathogens
to VIGAMOX 96
BOL Receives FDA Approval for Ofloxacin 96
Hi-Tech Pharmacal Receives FDA Clearance for Ofloxacin
Ophthalmic Solution 96
Vision Blue and DORC International Receives FDA Approval for
Trypan Blue 96
Pfizer Receives FDA Nod for Macugen® 96
Bausch & Lomb Bags FDA Approval for its Zylet™ 97
ISTA Pharmaceuticals Launches Istalol for Glaucoma Treatment
in the US 97
Falcon Unveils Trifluridine Ophthalmic Solution, 1% 97
Alimera Sciences Unveils Soothe™ Emollient Eye Drops 97
Novartis Introduces Zaditen in Japan 97
Falcon Releases Brimonidine Tartrate Ophthalmic Solution, 0.2% 97
Alcon Receives Approval for Olopatadine (Patanol) 98
Pharmacia Receives FDA Approval for Latanoprost Ophthalmic
Solution 98
US FDA Approves Allergan's New Acular LS 0.4% for Ocular Pain
Reduction 98
Allergan Obtains FDA Approval for Zymar 98
Taiwanese Researchers Introduces Thermosensitive Ophthalmic Drop 98
Alcon Introduces Systane Lubricant Eye Drops 98
Allergan Releases Restasis for Dry Eye Treatment 99
Biosyntrx Launches BioTears 99
Novartis to Introduce Pirenzepine Ophthalmic Gel 99

8. RECENT INDUSTRY ACTIVITY 100
Bausch & Lomb Takes Over Zirgan® 100
Inspire and Santen Secure Japanese Approval for DIQUAS 100
Asahi Kasei Pharma and Altheos Enter into License Agreement 100
OPKO Health Takes Over Pharmacos Exakta 101
Alcon Acquires Rights of Two Ophthalmic Pharmaceutical
Products of Sirion 101
QLT Secures Rights from Othera Pharmaceuticals 101
Novartis Acquires 77% Stake in Alcon 101
Pfizer Acquires Wyeth 102
Pieris Collaborates With Allergan to Treat Ocular Disorders 102
Bausch & Lomb Takes Over Commercial Assets of Tubilux 102
I-Therapeutix Changes Its Name to Ocular Therapeutix 102
Alcon Signs Collaborative Research Agreement with AstraZeneca 102
Fera Pharmaceuticals Takes Over Seven Ophthalmic Ointments of
Fougera 103
Bausch & Lomb Obtains Approval for Novel Ophthalmic Product 103
Alcon to Set Up Manufacturing Facility in Singapore 103
Inspire Pharmaceuticals Selects Clinipace to Conduct Phase II
Clinical Trials 103
Regeneron and Bayer to Extend Global Development Collaboration 104
Sucampo Obtains Rights to Commercialize Rescula 104
Santen and Merck Inks Licensing Agreement 104
InSite Vision Inks Licensing and Distribution Agreement with
Nitten 105
OPKO Terminates Phase III Trial of Bevasiranib 105
Sirion Therapeutics Signs Agreement with Advanced Vision Research 105
Bausch & Lomb and Pfizer Ink Co-Promotion Agreement 106
NanoViricides Inks Material Transfer Agreement for Ophthalmic
Antiviral 106
MacuCLEAR Partners with Mystic for Clinical Trials 106
Sohm Inks Private Label and Development Agreement with Indian
Company 107
Adeona Forms Research Collaboration with NNRI 107
Santen Receives Approval for TAPROS from MHLW 107
Otsuka and Acucela Ink Definitive Co-Development Deal for
Rebamipide 107
Canadian Bio Med Systems Obtains Licensing Rights for Two
Ophthalmic Products 108
Novartis Acquires Minority Stake in Alcon from Nestle 108
OPKO Acquires Development and Commercialization Rights to
Doxovir™ 108
InSite Vision Inks Licensing and Distribution Agreement with
Essex 108
arGentis Pharmaceuticals Obtains License for New Ophthalmic Drug 109
Opko Health Finalizes Vidus Ocular Take Over 109
InSite Vision Inks Licensing and Distribution Agreement with Biem 109
Bausch & Lomb Inks Collaborative Research Agreement with
Galapagos 109
PRP and Jerini Ink License and Development Agreement with
Jerini Ophthalmic 110
Akorn Inks Manufacturing and Supply Agreement with a US Company 110
Sirion and Bridge Pharma Sign Licensing Agreement 110
NicOx Extends Collaboration Agreement with Pfizer 110
Bausch & Lomb Acquires IOL Maker, Eyeonics 110
Akorn Inks Manufacture &Supply Agreement for Ophthalmic Solution 111
CrystalGenomics Enters Into R&D Agreement with Bausch & Lomb 111

9. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER 112
Genaera Corporation Quits Evizon Clinical Trials 112
Eyetech Inc Divests Anti-Platelet Derived Growth Factor (PDGF)
Aptamer Program 112
Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs 112
Bausch & Lomb Acquire Soothe Products from Alimera 112
Froptix, Acuity, eXegenics Merge to Form Opko Corporation 113
Alimera, Emory Collaborate Over Potential Ophthalmic
Treatments Using Novel Antioxidants 113
Santen Signs Agreement with Vistakon Pharmaceuticals for US
Launch of Iquix® 113
Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections 113
QLT Takes Over Forsight Newco II, Inc 113
Phase IV Clinical Trials Of Macugen® 114
Results Of Phase II Clinical Trials - Macugen® 114
Bausch & Lomb Purchases OTC Allergy Drugs of Alimera 114
Phase II Trial of Acuity Pharmaceutical's Bevasiranib 115
Advanced Refractive Technologies Acquires a Subsidiary of UTEK
Corporation 115
Sirion Therapeutics Acquires Sytera 115
Teva Pharmaceuticals Acquires Ivax 115
Alcon Enters into an Agreement with Amgen 115
QLT Signs an Agreement with Retinagenix 115
NicOx Enters into Licensing Agreement with Pfizer 116
OccuLogix Signs Agreement to Acquire SOLX 116
ISTA Receives License from Senju for Allergy Treatments 116
Acuity Receives License for Nchlorotaurine 116
Akorn and AVR Enter into Commercial Manufacturing & Supply
Agreement 116
Lantibio Signs Agreement with TRB Chemedica 117
Argentis and Southern College of Optometry Enter into Agreement 117
Bausch & Lomb Enters into Marketing Agreement with Novartis 117
Santen Pharmaceuticals and Ube Industries to Develop Glaucoma
Therapy Jointly 117
Santen Pharmaceutical and CytoPathfinder Signs an Agreement 117
Kalypsys Inks an Agreement with Alcon, Inc 117
Combination RX Enters into a Collaboration Agreement with Fovea 117
Par Pharmaceutical Joins Force with Spectrum Pharmaceuticals 118
Isotechnika Sells Eye Drug Rights to Lux Biosciences 118
Alimera Sciences Collaborates With CYNACON 118
Novartis Inks an In-Licensing Agreement with Otsuka 118
Alimera Sciences Commences Phase III Trials for Medidur™ 119
SurModics Acquires InnoRx 119
Bausch & Lomb Acquires Shandong Chia Tai Freda Pharmaceutical
Group 119
OSI Pharmaceuticals Takes Over Eyetech Pharmaceuticals 119
Pfizer Acquires Angiosyn 119
Bausch & Lomb Collaborates with PTC Therapeutics 120
AMRI Enters into Research Collaboration with Alcon 120
Bausch & Lomb Bags License from Cephalon 120
PediaMed and Allergan Sign a Co-Promotion Agreement 120
SurModics Bags Option to Acquire Exclusive Rights from Rutgers
University 120
Sankyo Co. and Santen Pharmaceutical Sign Agreement 120
Acuity Pharmaceuticals Enters into Agreement with Intradigm
Corporation 120
Apotex Inks Marketing Agreement with Akorn 121
Novartis Enters into an Agreement with Senju Pharmaceutical 121
Novartis Strikes a Licensing Deal with Otsuka Pharmaceutical 121
Custom RX recalls Trypan Blue 0.06% Ophthalmic Solution 121
AMO Takes Over VISX 121
Advanced Medical Optics Acquires Ophthalmic Surgical Business
of Pfizer 121
Santen to Take Over Marketing Rights of Rescula from R-Tech Ueno 122
Alimera Sciences Inks Co-promotion Agreement with VISTAKON
Pharmaceuticals 122
Akorn Inks a Purchase and Supply Agreement with FDC 122
ISTA Pharmaceuticals Receives Marketing License From Senju
Pharmaceuticals 122
Pfizer Inc Acquires Pharmacia Corp 122
Allergan Takes Over Oculex Pharmaceuticals 122
Allergan Enters into an Agreement with Acadia 122

10. FOCUS ON SELECT GLOBAL PLAYERS 123
Akorn, Inc. (USA) 123
Alcon, Inc. (Switzerland) 123
Allergan, Inc. (USA) 124
Alimera Sciences, Inc. (USA) 125
Bausch & Lomb, Inc. (USA) 125
Genvec, Inc. (USA) 126
Glaxosmithkline Plc. (UK) 126
Inspire Pharmaceuticals, Inc. (USA) 126
ISTA Pharmaceuticals, Inc. (USA) 126
Merck & Co., Inc. (USA) 127
Novartis Ophthalmics (Canada) 127
Opko Health, Inc. (USA) 128
Otsuka Pharmaceutical Co., Ltd. (Japan) 128
Pfizer, Inc. (USA) 128
QLT, Inc. (Canada) 128
Santen Pharmaceutical Co. (Japan) 129
Santen Inc. (US) 129

11. GLOBAL MARKET PERSPECTIVE 130
Table 7: World Recent Past, Current and Future Analysis for
Ophthalmic Pharmaceutical Drugs by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 130

Table 8: World Historic Review for Ophthalmic Pharmaceutical
Drugs by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 131

Table 9: World 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets for Years 2005, 2010, and 2015 (includes
corresponding Graph/Chart) 132

Table 10: World Recent Past, Current and Future Analysis for
Glaucoma Treatment Drugs by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 133

Table 11: World Historic Review for Glaucoma Treatment Drugs
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 134

Table 12: World 11-Year Perspective for Glaucoma Treatment
Drugs by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
2005, 2010, and 2015 (includes corresponding Graph/Chart) 135

Table 13: World Recent Past, Current and Future Analysis for
Ophthalmic Anti-allergy Drugs by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 136

Table 14: World Historic Review for Ophthalmic Anti-allergy
Drugs by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 137

Table 15: World 11-Year Perspective for Ophthalmic
Anti-allergy Drugs by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets for
Years 2005, 2010, and 2015 (includes corresponding
Graph/Chart) 138

Table 16: World Recent Past, Current and Future Analysis for
Ophthalmic Anti-infective Drugs by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 139

Table 17: World Historic Review for Ophthalmic Anti-infective
Drugs by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 140

Table 18: World 11-Year Perspective for Ophthalmic
Anti-infective Drugs by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets for Years 2005, 2010, and 2015 (includes
corresponding Graph/Chart) 141

Table 19: World Recent Past, Current and Future Analysis for
Dry Eye Treatment Drugs by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 142

Table 20: World Historic Review for Dry Eye Treatment Drugs by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 143

Table 21: World 11-Year Perspective for Dry Eye Treatment
Drugs by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
2005, 2010, and 2015 (includes corresponding Graph/Chart) 144

Table 22: World Recent Past, Current and Future Analysis for
Ophthalmic Anti-inflammatory Drugs by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 145

Table 23: World Historic Review for Ophthalmic
Anti-inflammatory Drugs by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2007
(includes corresponding Graph/Chart) 146

Table 24: World 11-Year Perspective for Ophthalmic
Anti-inflammatory Drugs by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets for Years 2005, 2010, and 2015 (includes
corresponding Graph/Chart) 147

Table 25: World Recent Past, Current and Future Analysis for
Back of Eye Treatment Drugs by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 148

Table 26: World Historic Review for Back of Eye Treatment
Drugs by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 149

Table 27: World 11-Year Perspective for Back of Eye Treatment
Drugs by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
2005, 2010, and 2015 (includes corresponding Graph/Chart) 150

Table 28: World Recent Past, Current and Future Analysis for
Other Treatment Drugs by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 151

Table 29: World Historic Review for Other Ophthalmic Treatment
Drugs by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 152

Table 30: World 11-Year Perspective for Other Ophthalmic
Treatment Drugs by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets for
Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 153

12. THE UNITED STATES 154
A.Market Analysis 154
Outlook 154
Recession Relights Sales of OTC Drugs in Pharmaceutical
Industry 154
Emphasis on Greater Awareness About Ophthalmic Disorders 154
Growth Drivers In a Capsule 155
Impediments to Growth 155
Market Fact Sheet 155
Glaucoma Market: A Primer 156
Patent Expiries of Key Glaucoma Drugs 156
Awareness Among Patients 156
High Costs 157
Treatment Patterns Adopted By Doctors 157
The All Consuming Issue of Compliance 157
Drug Brands & Their Patient Compliance Score 158
Market Share Statistics 158
Table 31: The US Market for Ophthalmic Pharmaceutical Drugs
(2004-2007): Percentage Market Share Breakdown of Leading
Players - Alcon Laboratories, Allergan, Novartis
Pharmaceutical, Pfizer/OSI Pharmaceuticals, Bausch & Lomb
Pharmaceuticals, and Others (includes corresponding
Graph/Chart) 158

Table 32: The US Market for Glaucoma Pharmaceutical
Products by Leading Drugs (2008 & 2009): Market Share
Breakdown in terms of Prescription Volume for Xalatan,
Lumigan, Alphagan P, Travatan and Others (includes
corresponding Graph/Chart) 159

Table 33: Leading Glaucoma Pharmaceutical Products in the
US (2008, 2010 & 2012): Percentage Breakdown of Value Sales
for Xalatan/Xalcom, Cosopt, Lumigan, Travatan, Alphagan,
Combigan, Generic Timolol and Others (includes
corresponding Graph/Chart) 159
Select Glaucoma Pharmaceuticals Presently Approved/ In Pipeline 160
Table 34: Top 10 Brands of Eye/Lens Care in the US:
Breakdown of Dollar and Unit Sales Through Drug Stores,
Supermarkets and Discount Stores For the Year Ended
November 2007 (In US$ 000 and Thousand Units) 161

Table 35: Top 5 Eye Care Products in the US: Breakdown of
Dollar Sales Through Food, Drug and Mass Market Channels
for the Year Ended July 2007 (In US$ Million) (includes
corresponding Graph/Chart) 161

Table 36: Age-Related Wet Macular Degeneration Market in
the United States (2004-2006): Percentage Market Share
Breakdown of Leading Players - QLT Inc/Novartis
Pharmaceutical Corp, and Eyetech Pharmaceuticals (OSI) /
Pfizer. (includes corresponding Graph/Chart) 162

Table 37: Ocular Allergy Market in the United States
(2004-2007): Percentage Market Share Breakdown of Leading
Players - Alcon Laboratories, Novartis Pharmaceutical,
Bausch & Lomb Pharmaceuticals, Allergan, Santen, and Others
(includes corresponding Graph/Chart) 162

Table 38: Ocular NSAIDs (Topical Non-Steroidal
Anti-Inflammatory Drugs) Market in the United States
(2007): Percentage Market Share Breakdown of Leading
Players - Allergan, Inc. Novartis Pharmaceutical Corp.,
Alcon Laboratories, Inc., and ISTA Pharmaceuticals
(includes corresponding Graph/Chart) 163

Table 39: Age-Related Macular Degeneration Market in the
United States (2006, 2009 & 2012): Dollar Sales of Major
Branded Drugs - Visudyne, Macugen, and Lucentis (In US$
Million) (includes corresponding Graph/Chart) 163
Major Anti-Glaucoma Drugs Available in the United States:
Year 2006 164
Major Drugs Available in the United States for the
Treatment of AMD: Year 2005 164
Drugs in the Pipeline for the Treatment of AMD in the
United States: Year 2005 165
Major Drugs Available in the United States for the Control
of Dry Eye: Year 2005 165
US Market for Dry Eye: Drugs in the Pipeline Year 2005 165
Companies Actively Involved in Manufacturing Drugs for Dry
Eye: Year 2005 166
Major Drugs Available in the United States for the
Treatment of Ocular Allergies: Year 2005 166
US Market for Ocular Allergies: Drugs in the Pipeline: Year
2005 167
Statistical Findings On Ophthalmic Diseases in the United
States 167
Table 40: Prevalence of Age-Related Macular Degeneration:
Percentage Breakdown by Wet AMD & Intermediate Dry AMD by
Age Group for the Year 2005 (includes corresponding
Graph/Chart) 167

Table 41: Prevalence of Age-Related Wet Macular
Degeneration in the United States for the Years 2006, 2009, &
2012 (In Millions of Individuals) (includes corresponding
Graph/Chart) 168

Table 42: Number of Individuals Treated for Wet AMD in the
United States (In Thousands) for the Years 2006, 2009 &
2015 (includes corresponding Graph/Chart) 168

Table 43: Prevalence of Ocular Hypertension (OHT) in the
United States for the Years 2006, 2009, & 2011 (In Millions
of Individuals) (includes corresponding Graph/Chart) 168

Table 44: Prevalence of Primary Open Angle Glaucoma (POAG)
in the United States for the Years 2006, 2009, & 2011 (In
Millions of Individuals) (includes corresponding
Graph/Chart) 169

Table 45: Prevalence of Normal Tension Glaucoma (NTG) in
the United States for the Years 2006, 2009, & 2011 (In
Thousand Individuals) (includes corresponding Graph/Chart) 169

Table 46: Prevalence of Exfoliative Glaucoma (EG) in the
United States for the Years 2006, 2009, & 2011 (In Thousand
Individuals) (includes corresponding Graph/Chart) 169

Table 47: Prevalence of Pigmentary Glaucoma (PG) in the
United States for the Years 2006, 2009, & 2011 (In Thousand
Individuals) (includes corresponding Graph/Chart) 170

Table 48: Number of Individuals Treated for Glaucoma in the
United Sates (2006, 2009 and 2011): Breakdown by Type -
Ocular Hypertension (OHT), Primary Open Angle Glaucoma
(POAG), Normal Tension Glaucoma (NTG), Pigmentary Glaucoma
(PG) and Exfoliative Glaucoma (EG) (In 000 Individuals)
(includes corresponding Graph/Chart) 170

Table 49: Prevalence of Ocular Allergy in the United States
for the Years 2006, 2009, & 2012 (In Millions of
Individuals) (includes corresponding Graph/Chart) 171

Table 50: Number of Individuals Treated for Ocular Allergy
in the United States (In Million) for the Years 2006, 2009 &
2012 (includes corresponding Graph/Chart) 171

Table 51: Prevalence of Cataract in the United States:
Percentage Breakdown by Age Group for the Year 2005
(includes corresponding Graph/Chart) 171

Table 52: Prevalence of Cataract in the United States for
the Years 2006, 2009, & 2012 (In Millions of Individuals)
(includes corresponding Graph/Chart) 172

Table 53: Number of Individuals Treated for Cataract With
Ocular NSAIDs (Topical Non- Steroidal Anti-Inflammatory
Drugs) in the United States for the Years 2006, 2009 & 2012
((In Millions) (includes corresponding Graph/Chart) 172

Table 54: Prevalence of Dry Eye in the United States for
the Years 2006, 2009, & 2012 (In Millions of Individuals)
(includes corresponding Graph/Chart) 172

Table 55: Number of Individuals Treated for Dry Eye in the
United States (In 000s) for the Years 2006, 2009 & 2012
(includes corresponding Graph/Chart) 173
B.Market Analytics 173
Table 56: US Recent Past, Current and Future Analysis for
Ophthalmic Pharmaceutical Drugs by Therapeutic Category -
Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 173

Table 57: US Historic Review for Ophthalmic Pharmaceutical
Drugs by Therapeutic Category - Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 174

Table 58: US 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010 and 2015 (includes corresponding
Graph/Chart) 175

13. CANADA 176
A.Market Analysis 176
Outlook 176
Lack of Awareness: A Key Issue 176
B.Market Analytics 177
Table 59: Canadian Recent Past, Current and Future Analysis
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category-
Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 177

Table 60: Canadian Historic Review for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Glaucoma,
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation,
Back of Eye and Others Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 178

Table 61: Canadian 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010 and 2015 (includes corresponding
Graph/Chart) 179

14. JAPAN 180
A.Market Analysis 180
Outlook 180
Growth Drivers 180
Market Data Statistics 180
Leading Ophthalmic Pharmaceutical Brands In the Market 180
Table 62: Japanese Market for Prescription Ophthalmic
Drugs: Percentage Breakdown by Therapeutic Area -
Glaucoma, Infection, Corneal Disorder, Ocular Allergy,
Surgical Preparation, Steroid, Cataract, and Others.
(includes corresponding Graph/Chart) 181
B.Market Analytics 181
Table 63: Japanese Recent Past, Current and Future Analysis
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category-
Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 181

Table 64: Japanese Historic Review for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Glaucoma,
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation,
Back of Eye and Others Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 182

Table 65: Japanese 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010 and 2015 (includes corresponding
Graph/Chart) 183

15. EUROPE 184
A.Market Analysis 184
Outlook 184
A Market Primer 184
Drug Reimbursement in Europe 184
B.Market Analytics 186
Table 66: European Recent Past, Current and Future Analysis
for Ophthalmic Pharmaceutical Drugs by Country/Region -
France, Germany, Italy, UK, Spain and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 186

Table 67: European Historic Review for Ophthalmic
Pharmaceutical Drugs by Country/Region - France, Germany,
Italy, UK, Spain and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 187

Table 68: European 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Country/Region - Percentage
Breakdown of Dollar Sales for France, Germany, Italy, UK,
Spain and Rest of Europe Markets for Years 2005, 2010, and
2015 (includes corresponding Graph/Chart) 188

Table 69: European Recent Past, Current and Future Analysis
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category-
Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 189

Table 70: European Historic Review for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Glaucoma,
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation,
Back of Eye and Others Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 190

Table 71: European 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010 and 2015 (includes corresponding
Graph/Chart) 191

15a. FRANCE 192
A.Market Analysis 192
Outlook 192
B.Market Analytics 193
Table 72: French Recent Past, Current and Future Analysis
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category-
Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 193

Table 73: French Historic Review for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Glaucoma,
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation,
Back of Eye and Others Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 194

Table 74: French 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010 and 2015 (includes corresponding
Graph/Chart) 195

15b. GERMANY 196
Market Analysis 196
Table 75: German Recent Past, Current and Future Analysis
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category-
Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 196

Table 76: German Historic Review for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Glaucoma,
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation,
Back of Eye and Others Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 197

Table 77: German 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010, and 2015 (includes
corresponding Graph/Chart) 198

15c. ITALY 199
Market Analysis 199
Table 78: Italian Recent Past, Current and Future Analysis
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category-
Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 199

Table 79: Italian Historic Review for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Glaucoma,
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation,
Back of Eye and Others Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 200

Table 80: Italian 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010, and 2015 (includes
corresponding Graph/Chart) 201

15d. THE UNITED KINGDOM 202
A.Market Analysis 202
Outlook 202
B.Market Analytics 203
Table 81: UK Recent Past, Current and Future Analysis for
Ophthalmic Pharmaceutical Drugs by Therapeutic Category-
Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 203

Table 82: UK Historic Review for Ophthalmic Pharmaceutical
Drugs by Therapeutic Category - Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 204

Table 83: UK 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010, and 2015 (includes
corresponding Graph/Chart) 205

15e. SPAIN 206
A.Market Analysis 206
Outlook 206
How & Why the Health Insurance System in Spain is Conducive? 206
Pharmaceutical Reimbursement Reforms in Spain (1996-2002) 206
B.Market Analytics 208
Table 84: Spanish Recent Past, Current and Future Analysis
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category-
Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 208

Table 85: Spanish Historic Review for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Glaucoma,
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation,
Back of Eye and Others Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 209

Table 86: Spanish 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010 and 2015 (includes corresponding
Graph/Chart) 210

15f. REST OF EUROPE 211
A.Market Analysis 211
Outlook 211
B.Market Analytics 212
Table 87: Rest of Europe Recent Past, Current and Future
Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic
Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 212

Table 88: Rest of Europe Historic Review for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Glaucoma,
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation,
Back of Eye and Others Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 213

Table 89: Rest of Europe 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010, and 2015 (includes
corresponding Graph/Chart) 214

16. ASIA-PACIFIC 215
A.Market Analysis 215
Outlook 215
B.Market Analytics 216
Table 90: Asia-Pacific Recent Past, Current and Future
Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic
Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 216

Table 91: Asia-Pacific Historic Review for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Glaucoma,
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation,
Back of Eye and Others Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 217

Table 92: Asia-Pacific 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010 and 2015 (includes corresponding
Graph/Chart) 218

17. LATIN AMERICA 219
Market Analysis 219
Table 93: Latin American Recent Past, Current and Future
Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic
Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 219

Table 94: Latin America Historic Review for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Glaucoma,
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation,
Back of Eye and Others Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 220

Table 95: Latin American 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010, and 2015 (includes
corresponding Graph/Chart) 221

18. REST OF WORLD 222
A.Market Analysis 222
Outlook 222
B.Market Analytics 223
Table 96: Rest of World Recent Past, Current and Future
Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic
Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye,
Anti-inflammation, Back of Eye and Others Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 223

Table 97: Rest of World Historic Review for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category - Glaucoma,
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation,
Back of Eye and Others Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 224

Table 98: Rest of World 11-Year Perspective for Ophthalmic
Pharmaceutical Drugs by Therapeutic Category- Percentage
Breakdown of Dollar Sales for Glaucoma, Anti-allergy,
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and
Others for Years 2005, 2010, and 2015 (includes
corresponding Graph/Chart) 225

COMPETITION

Total Companies Profiled: 95 (including Divisions/Subsidiaries - 126)

---------
Region/Country Players
---------
The United States 49
Canada 4
Japan 8
Europe 39
France 6
Germany 4
The United Kingdom 4
Italy 4
Spain 2
Rest of Europe 19
Asia-Pacific (Excluding Japan) 18
Latin America 1
Middle-East 7
---------

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos